See All Slides - tctmd.com

Slides

Presentation TCT 2012

The 2012 ESC Mitral Valve Guidelines: What's New, and How Should They Affect Practice?

Presenter: Francesco Maisano

October 23, 2012

Presentation TCT 2012

TCT-45. Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-world Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

Presenter: James Hermiller Jr

October 23, 2012

Presentation TCT 2012

ELM Presentation

Presenter: J. Dawn Abbott

October 23, 2012

Presentation TCT 2012

Vascular Access Choice and Radiation Exposure

Presenter: Sanjit Jolly

October 23, 2012

Presentation TCT 2012

Preclinical Review: Experimental Pathways for Evaluation of Drug Transfer, Tissue Pharmacokinetics, and Vascular Effects

Presenter: Elazer Edelman

October 23, 2012

Presentation TCT 2012

Debate I. Is Endovascular Intervention the First-line Therapy for CLI? Pro!

Presenter: Tony Das

October 23, 2012

Presentation TCT 2012

ABSORB (Abbott Vascular) Clinical Program to Date (and EXTEND Results): Strengths, Limitations, Including the 6-month Unknowns of the ABSORB Stent

Presenter: Antonio Bartorelli

October 23, 2012

Presentation TCT 2012

Didactic Overview(5)

Presenter: Regina Deible

October 23, 2012

Presentation TCT 2012

Supply Chain Management: Lowering Costs and Utilization

Presenter: Michael Guiry

October 23, 2012

Presentation TCT 2012

TCT-80. Incidence of Periprocedual Myocardial Infarction in Chronic Total Occlusion PCI and Impact on Clinical Outcome

Presenter: Tasuku Hasegawa

October 23, 2012

Advertisement

Slides

The 2012 ESC Mitral Valve Guidelines: What's New, and How Should They Affect Practice?

TCT-45. Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-world Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

ELM Presentation

Vascular Access Choice and Radiation Exposure

Preclinical Review: Experimental Pathways for Evaluation of Drug Transfer, Tissue Pharmacokinetics, and Vascular Effects

Debate I. Is Endovascular Intervention the First-line Therapy for CLI? Pro!

ABSORB (Abbott Vascular) Clinical Program to Date (and EXTEND Results): Strengths, Limitations, Including the 6-month Unknowns of the ABSORB Stent

Didactic Overview(5)

Supply Chain Management: Lowering Costs and Utilization

TCT-80. Incidence of Periprocedual Myocardial Infarction in Chronic Total Occlusion PCI and Impact on Clinical Outcome

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content